Describe the molecular pathway of atherosclerosis?

Molecular Pathway of Atherosclerosis

Atherosclerosis is fundamentally an inflammatory disease initiated by LDL accumulation in the arterial wall, progressing through endothelial dysfunction, immune cell recruitment, foam cell formation, and ultimately plaque rupture leading to thrombosis. 1

Initiation: LDL Entry and Modification

The atherosclerotic process begins when LDL particles enter the arterial intima through passive molecular sieving, a process that accelerates with higher plasma LDL concentrations. 2 Once trapped in the subendothelial space (unable to penetrate the elastic laminas), these LDL particles undergo critical modifications:

• Oxidative modification of LDL is essential before macrophages can take them up to form foam cells 2
• Oxidative stress, driven by NAD(P)H oxidases activated by mechanical forces (hypertension), angiotensin II, and cytokines, generates reactive oxygen species that oxidize LDL 1
• Superoxide anions react with nitric oxide to form peroxynitrite, which further oxidizes lipids and makes them highly atherogenic 1

Endothelial Dysfunction and Activation

Major injurious factors—cigarette smoking, hypertension, atherogenic lipoproteins, and hyperglycemia—trigger endothelial dysfunction, the gateway to atherosclerosis. 1

This dysfunction manifests through:

• Loss of vasodilator capacity as reactive oxygen species shorten the half-life of endothelium-derived nitric oxide 1
• Upregulation of adhesion molecules (ICAM-1, VCAM-1, P-selectin, E-selectin) on the luminal endothelial surface 1
• Secretion of chemotactic cytokines (interleukin-1, interleukin-6, tumor necrosis factor-α, monocyte chemotactic protein-1) that recruit inflammatory cells 1

Immune Cell Recruitment and Foam Cell Formation

Circulating monocytes adhere to activated endothelium via selectins, then firmly attach through integrin-ICAM/VCAM interactions, and transmigrate into the subendothelial space. 1, 3

The inflammatory cascade proceeds as follows:

• Monocytes transform into macrophages upon entering the arterial wall 1
• Macrophages internalize oxidized LDL through scavenger receptors (not the normal LDL receptor), becoming lipid-laden foam cells 2
• Foam cells accumulate to form fatty streaks, the earliest pathological lesion visible in childhood 2
• Triglyceride-rich lipoproteins can also be taken up directly via VLDL receptors, providing an alternative foam cell formation pathway 2

Macrophages are the hallmark cells of atherosclerotic plaques, driving both plaque progression and destabilization. 2

Plaque Progression and Smooth Muscle Cell Involvement

The lesion evolves beyond simple foam cell accumulation:

• Inflammatory mediators activate medial smooth muscle cells, causing them to proliferate and migrate into the subintimal space 1
• Smooth muscle cells produce extracellular matrix proteins (collagen, elastin) that form a fibrous cap over the lipid-rich necrotic core 4
• Activated T cells (particularly T helper-1 cells) accumulate within growing lesions, secreting pro-inflammatory cytokines that perpetuate the inflammatory cycle 5
• Mast cells also contribute to the ongoing inflammatory milieu 1

Plaque Destabilization and Rupture

The transition from stable plaque to acute thrombotic event involves enzymatic degradation of the protective fibrous cap. 1

Critical destabilizing mechanisms include:

• Macrophages secrete metalloproteinases and cathepsins that break down collagen in the fibrous cap 1, 2
• Oxidized LDL promotes smooth muscle cell apoptosis in the plaque cap, further weakening its structure 1
• Cap rupture exposes the thrombogenic necrotic core to circulating blood 1
• Tissue factor release triggers thrombosis, leading to coronary occlusion and acute myocardial infarction 1

Systemic Amplification Through Humoral Factors

The renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system amplify both hypertension and direct vascular injury. 1

Additional perpetuating factors:

• Angiotensin II directly activates NAD(P)H oxidases, increasing oxidative stress 1
• Deficiencies in vasodilators (nitric oxide, prostacyclin, natriuretic peptides) impair endothelial protective mechanisms 1
• Growth factors and inflammatory cytokines maintain chronic low-grade vascular inflammation 1

Key Molecular Markers of the Pathway

Measurable inflammatory markers reflect different stages of the atherosclerotic process: oxidized LDL (initiating factor), adhesion molecules (endothelial activation), interleukin-6 (cytokine signaling), C-reactive protein (hepatic acute-phase response), and elevated leukocyte count (cellular inflammation). 1

Clinical Implications

Atherosclerosis begins in childhood and progresses over decades, with every 10-15 mg/dL increase in non-HDL cholesterol equivalent to one additional year of vascular aging. 1 This underscores that LDL lowering throughout life—not just in middle age—is critical for preventing advanced disease, as established atherosclerosis must be regressed, not merely stabilized. 1

The foundational role of LDL in atherogenesis remains axiomatic despite discovery of numerous inflammatory pathways, making LDL reduction the primary therapeutic target. 1